acquired
Stage
About
89bio is a clinical-stage biopharmaceutical company developing therapies focused on liver and cardiometabolic diseases, utilizing FGF21-based metabolic regulators.
Explore 89bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.